Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Innovent Biologics, Inc.

Market Cap 112B 129B 16.49B 14.27B 13.16B 12.31B 22.97B 1,571B 23.49B 156B 60.63B 761B 61.9B 60.57B 2,646B P/E Ratio 2026 *
47.8x
P/E Ratio 2027 * 30.2x
Enterprise Value 95.07B 110B 14.03B 12.14B 11.2B 10.47B 19.55B 1,337B 19.98B 133B 51.59B 647B 52.67B 51.54B 2,251B EV / Sales 2026 *
5.06x
EV / Sales 2027 * 4.14x
Free-Float
93.74%
Yield 2026 *
-
Yield 2027 * 0.06%
1 day-1.88%
1 week-5.07%
Current month-12.48%
1 month-18.94%
3 months-14.98%
6 months-12.63%
Current year-4.33%
1 week 69.55
Extreme 69.55
79.8
1 month 69.55
Extreme 69.55
90.75
Current year 69.55
Extreme 69.55
93.8
1 year 69.55
Extreme 69.55
109.1
3 years 27.3
Extreme 27.3
109.1
5 years 18.06
Extreme 18.06
109.1
10 years 14
Extreme 14
109.1
Manager TitleAgeSince
Chief Executive Officer 62 28/04/2011
Director of Finance/CFO 47 05/02/2024
Chief Tech/Sci/R&D Officer - 01/11/2020
Director TitleAgeSince
Chairman 62 28/04/2011
Director/Board Member 81 18/10/2015
Director/Board Member 67 04/06/2018
Date Insider Type Main position Quantity % Market Cap.
05-14Other

Director

-43,431 0.0025%
03-30Other

Director

39,366 0.0023%
03-30Other 24,226 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
-1.88%-5.07%-10.05%+93.76% 16.49B
+1.85%-2.43%+18.29%-18.64% 61.21B
+2.50%+4.43%+64.44%+218.90% 58.15B
-0.92%+28.60%+28.60%+28.60% 39.54B
+4.16%+16.25%-56.08%-64.88% 35.08B
+1.58%+0.42%+48.26%-37.05% 28.68B
+3.11%+7.28%+57.75%+74.90% 21.06B
+3.40%-7.85%+71.32%-61.51% 18.25B
+0.78%-1.57%+44.59%+101.10% 15.87B
+0.84%+0.74%+73.70%+329.04% 13.2B
Average +1.48%+1.42%+34.08%+66.42% 30.75B
Weighted average by Cap. +1.69%+1.50%+30.72%+56.35%

Financials

2026 *2027 *
Net sales 18.78B 21.72B 2.77B 2.4B 2.21B 2.07B 3.86B 264B 3.95B 26.28B 10.19B 128B 10.4B 10.18B 445B 22.1B 25.56B 3.26B 2.82B 2.6B 2.43B 4.54B 311B 4.65B 30.92B 11.99B 150B 12.24B 11.98B 523B
Net income 2.47B 2.86B 365M 316M 291M 272M 508M 34.73B 519M 3.46B 1.34B 16.82B 1.37B 1.34B 58.49B 3.55B 4.1B 523M 453M 418M 391M 729M 49.86B 745M 4.96B 1.92B 24.15B 1.96B 1.92B 83.98B
Net Debt -16.66B -19.27B -2.46B -2.13B -1.96B -1.84B -3.42B -234B -3.5B -23.31B -9.04B -113B -9.23B -9.03B -394B -20.13B -23.28B -2.97B -2.57B -2.37B -2.22B -4.14B -283B -4.23B -28.16B -10.92B -137B -11.15B -10.91B -477B
Logo Innovent Biologics, Inc.
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.
Employees
7,502
Date Price Change Volume
11/06/26 72.95 $ -1.88% 10,572,210
10/06/26 74.35 $ +1.64% 13,899,540
09/06/26 73.15 $ -0.14% 17,268,133
08/06/26 73.25 $ -4.37% 14,606,270
05/06/26 76.60 $ +0.26% 15,099,470
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
63.07CNY
Average target price
101.64CNY
Spread / Average Target
+61.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1801 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!